416 related articles for article (PubMed ID: 29261144)
1. PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.
Zhao H; Li D; Zhang B; Qi Y; Diao Y; Zhen Y; Shu X
Molecules; 2017 Dec; 22(12):. PubMed ID: 29261144
[TBL] [Abstract][Full Text] [Related]
2. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
3. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
4. Targeting PP2A inhibits the growth of triple-negative breast cancer cells.
Uddin MH; Pimentel JM; Chatterjee M; Allen JE; Zhuang Z; Wu GS
Cell Cycle; 2020 Mar; 19(5):592-600. PubMed ID: 32011210
[TBL] [Abstract][Full Text] [Related]
5. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA
Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525
[TBL] [Abstract][Full Text] [Related]
6. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Williams CB; Soloff AC; Ethier SP; Yeh ES
Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
10. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
[TBL] [Abstract][Full Text] [Related]
12. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
[TBL] [Abstract][Full Text] [Related]
14. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
[TBL] [Abstract][Full Text] [Related]
15. Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage response pathways in triple-negative breast cancer cells.
Fang Y; Zhang Q; Wang X; Yang X; Wang X; Huang Z; Jiao Y; Wang J
Int J Oncol; 2016 Mar; 48(3):1016-28. PubMed ID: 26783066
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides as Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC).
Chen Y; Tang Y; Mao B; Li W; Jin H; Zhang L; Liu Z
Molecules; 2018 Mar; 23(3):. PubMed ID: 29547591
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
Yam C; Mani SA; Moulder SL
Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer.
Guo W; Lin L; He X; He F; Wang C; Chen N; Wang Y
Crit Rev Oncog; 2017; 22(5-6):427-437. PubMed ID: 29604922
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.
Nouri Emamzadeh F; Word B; Cotton E; Hawkins A; Littlejohn K; Moore R; Miranda-Carbon G; Orish CN; Lyn-Cook B
Anticancer Res; 2020 Jul; 40(7):3669-3683. PubMed ID: 32620606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]